STING1 and ischemic cardiomyopathy: The above examples, and those additional studies summarized in Table 1, illustrate how a substantial body of literature has arisen in recent years indicating that cGAS-STING pathway activation takes place in both ischemic and non-ischemic cardiomyopathy and that blockade of cGAS-STING signaling improves cardiac outcomes in experimental models.